Unknown PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT05254249

Clinical Trial of Probiotic Supplementation in Psoriasis Vulgaris

Analysis of Gut Microbiota, Psoriasis Area and Severity Index, Interleukin-17, Tumor Necrosis Factor -α, Interleukin-10, and Foxp3 in Psoriasis Vulgaris After Supplementation With Lactobacillus Plantarum IS-10506

Sponsor: Dr. Soetomo General Hospital

Conditions Psoriasis Vulgaris

Interventions Lactobacillus Plantarum IS-10506 Placebo

Updated 4 times since 2022 Last updated: Feb 15, 2022 Started: Feb 7, 2022 Primary completion: Aug 31, 2022 Completion: Oct 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Psoriasis Vulgaris, this trial is ongoing. The trial is conducted by Dr. Soetomo General Hospital and has accumulated 4 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Mar 2024 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Mar 2022 — Mar 2024 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr. Soetomo General Hospital
Universitas Airlangga

Data source: Dr. Soetomo General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Surabaya, Indonesia